Our ambition is to build the next generation of innovative therapies in areas of significant unmet medical need. EH & RBB especially focuses on research and development of first in class therapies in the field of ophthalmology and emerging areas.

To prevent and treat vision loss in patients affected by conditions such as neovascular age-related macular degeneration, geographic atrophy, diabetic eye diseases, Stargardt disease, glaucoma and myopic macular degeneration, we are actively exploring novel pathophysiological pathways impacting disease progression. We are particularly interested in targets with strong links to human disease that can enhance our understanding of disease progression and/or facilitate earlier interventions. Key pathomechanisms of interest include vascular and neuronal dysfunction, lysosomal impairment and (neuro)inflammation.

In addition, we are committed to advancing disease-modifying and neuroprotective therapies for Alzheimer’s and Parkinson’s disease, as well as Amyotrophic Lateral Sclerosis. Therefore, we are open to collaborations aimed at validation of novel targets to treat Neurological diseases.  We also look for technological innovations that improve the delivery of biologics to the brain (e.g. endothelial targets enabling receptor-mediated transcytosis) or enhance the development of human disease-relevant organoids.

Women health is an emerging field of research at Boehringer Ingelheim. We are investigating non-hormonal, non-analgesic treatment strategies aimed at improving the quality of life for individuals living with endometriosis.

Furthermore, we are highly interested in curative approaches involving tissue-selective adeno-associated virus (AAV) gene therapy, as well as technologies that enable precise spatio-temporal control of gene expression or modulate immune responses.